ZERIA PHARMA, The Current Fiscal Year Ordinary Profit Revised Upward by 9%, Raises Record High Profit Forecast

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Wed Feb 5, 2025 4:00 pm JST Earnings

4559 ZERIA PHARMACEUTICAL CO.,LTD. 【J-GAAP】

Earnings Report

ZERIA PHARMACEUTICAL CO.,LTD. <4559> [TSE Prime] announced its financial results after the market closed on February 5th (16:00). The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending March 2025 (April to December) increased 12.9% from the same period last year, reaching 10.6 billion yen.

In addition, the full-year consolidated ordinary profit has been revised upward 9.1%, from the previous forecast of 11 billion yen to 12 billion yen (compared to 8.51 billion yen in the previous period), increasing the growth rate from 29.2% to 41.0%, further surpassing the previous forecast of record-high profits for three consecutive terms.

Based on the full-year plan announced by the company after the upward revision, our estimate of the consolidated ordinary profit for the October to March period (2H) is expected to increase 32.8%, from the previous forecast of 3.05 billion yen to 4.05 billion yen (compared to 3.01 billion yen in the same period of the previous year), increasing the growth rate from 1.1% to 34.2%.

In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit dropped to 2.71 billion yen, a 31.3% decrease compared to the same period last year. The operating profit margin decreased from 19.6% in the same period last year to 16.9%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Dec, 2022	51,729	8,550	6,957	5,980	135.3	91.8	Feb 2, 2023	J-GAAP
Apr - Dec, 2023	57,919	9,490	9,444	8,423	191.1	110.9	Feb 1, 2024	J-GAAP
Apr - Dec, 2024	64,773	10,246	10,661	8,226	186.6	88.8	Feb 5, 2025	J-GAAP
YoY	+11.8%	+8.0%	+12.9%	-2.3%	-2.3%

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024 Prev	43,578	4,541	3,051	2,439	55.3	23	Nov 6, 2024	J-GAAP
Oct - Mar, 2024 New	44,078	5,541	4,051	2,939	66.7	23	Feb 5, 2025	J-GAAP
Revision Rate	+1.1%	+22.0%	+32.8%	+20.5%	+20.5%

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2025 Prev	86,000	11,000	11,000	8,500	192.8	46	Nov 5, 2024	J-GAAP
Mar, 2025 New	86,500	12,000	12,000	9,000	204.2	46	Feb 5, 2025	J-GAAP
Revision Rate	+0.6%	+9.1%	+9.1%	+5.9%	+5.9%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	39,047	4,294	3,018	2,335	53.0	22	May 9, 2024	J-GAAP
Oct - Mar, 2024 Guidance	44,078	5,541	4,051	2,939	66.7	23	Feb 5, 2025	J-GAAP
YoY	+12.9%	+29.0%	+34.2%	+25.9%	+25.9%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	68,383	9,014	7,579	6,195	140.3	40	May 11, 2023	J-GAAP
Mar, 2024	75,725	9,621	8,513	7,731	175.4	44	May 9, 2024	J-GAAP
Mar, 2025 Guidance	86,500	12,000	12,000	9,000	204.2	46	Feb 5, 2025	J-GAAP
YoY	+14.2%	+24.7%	+41.0%	+16.4%	+16.4%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	21,241	4,163	3,949	3,027	68.7	19.6	Feb 1, 2024	J-GAAP
Jan - Mar, 2024	17,806	131	-931	-692	-15.7	0.7	May 9, 2024	J-GAAP
Apr - Jun, 2024	21,455	3,939	5,459	4,212	95.6	18.4	Aug 1, 2024	J-GAAP
Jul - Sep, 2024	20,967	2,520	2,490	1,849	42.0	12.0	Nov 6, 2024	J-GAAP
Oct - Dec, 2024	22,351	3,787	2,712	2,165	49.1	16.9	Feb 5, 2025	J-GAAP
YoY	+5.2%	-9.0%	-31.3%	-28.5%	-28.5%